Document is current
Any future updates will be listed below
-
Authors
Amstler, Stephan
Streiter, Gertraud
Pfurtscheller, Cathrin
Forer, Lukas
Di Maio, Silvia
Weissensteiner, Hansi
Paulweber, Bernhard
Schönherr, Sebastian
Kronenberg, Florian
Coassin, Stefan https://orcid.org/0000-0001-5677-8979
- License Information
-
More Information
Article History
Received: 6 March 2024
Accepted: 1 October 2024
First Online: 8 October 2024
Declarations
:
: The 1000G samples were obtained from the Coriell Sample Repository (Camden, NJ, USA). The samples of the European dataset were drawn from the Central-European SAPHIR study previously screened for mutations in the KIV-2 region by ultra-deep targeted sequencing [ ]. Informed consent was obtained from each participant and the analysis was carried out in accordance with the local ethics committee (Salzburg, Austria, EK Nr: 1074/2021). All research was conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: SC has received honoraria from Novartis AG (Basel, CH) and Silence Therapeutics PLC (London, UK) for consultancy on <i>LPA</i> genetics. FK has received honoraria from Novartis AG, CRISPR Therapeutics, Silence Therapeutics, Roche, and Amgen for consultancy on Lp(a) as well as lecture fees. LF has received honoraria from Novartis AG (Basel, CH). All other authors declare no competing interests.
